MedTrace Logo

Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection

NCT00004278 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES:

I. Evaluate the efficacy of ganciclovir (12 mg/kg per day) versus no treatment in neonates with symptomatic congenital cytomegalovirus infection with central nervous system disease.

Conditions

  • Cytomegalovirus Infections

Interventions

DRUG

ganciclovir

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • National Center for Research Resources (NCRR)

    lead NIH

Principal Investigators

  • Richard J. Whitley

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
0 Years
Max Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004278 on ClinicalTrials.gov